SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Evolving Management Paradigm for Stable Ischemic Heart Disease Patients: JACC Review Topic of the Week

Boden, WE; Marzilli, M; Crea, F; Mancini, GBJ; Weintraub, WS; Taqueti, VR; Pepine, CJ; Escaned, J; Al-Lamee, R; Gowdak, LHW; et al. Boden, WE; Marzilli, M; Crea, F; Mancini, GBJ; Weintraub, WS; Taqueti, VR; Pepine, CJ; Escaned, J; Al-Lamee, R; Gowdak, LHW; Berry, C; Kaski, JC; Chronic Myocardial Ischemic Syndromes Task Force (2023) Evolving Management Paradigm for Stable Ischemic Heart Disease Patients: JACC Review Topic of the Week. Journal of the American College of Cardiology, 81 (5). pp. 55-514. ISSN 0735-1097 https://doi.org/10.1016/j.jacc.2022.08.814
SGUL Authors: Kaski, Juan Carlos

[img] Microsoft Word (.docx) Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (399kB)
[img] Microsoft PowerPoint (Figure 1) Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (138kB)
[img]
Preview
PDF (Figure 2) Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (3MB) | Preview
[img]
Preview
PDF (Figure 3) Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (2MB) | Preview
[img] Microsoft PowerPoint (Central illustration) Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (58kB)

Abstract

Management of stable coronary artery disease (CAD) has been based on the assumption that flow-limiting atherosclerotic obstructions are the proximate cause of angina and myocardial ischemia in most patients and represent an important target for revascularization. However, the role of revascularization in reducing long-term cardiac events in these patients has been limited mainly to those with left main disease, 3-vessel disease with diabetes, or decreased ejection fraction. Mounting evidence indicates that nonepicardial coronary causes of angina and ischemia, including coronary microvascular dysfunction, vasospastic disorders, and derangements of myocardial metabolism, are more prevalent than flow-limiting stenoses, raising concerns that many important causes other than epicardial CAD are neither considered nor probed diagnostically. There is a need for a more inclusive management paradigm that uncouples the singular association between epicardial CAD and revascularization and better aligns diagnostic approaches that tailor treatment to the underlying mechanisms and precipitants of angina and ischemia in contemporary clinical practice.

Item Type: Article
Additional Information: © 2023. This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/
Keywords: 1102 Cardiorespiratory Medicine and Haematology, 1117 Public Health and Health Services, Cardiovascular System & Hematology
SGUL Research Institute / Research Centre: Academic Structure > Molecular and Clinical Sciences Research Institute (MCS)
Journal or Publication Title: Journal of the American College of Cardiology
ISSN: 0735-1097
Dates:
DateEvent
7 February 2023Published
30 January 2023Published Online
15 August 2022Accepted
Publisher License: Creative Commons: Attribution-Noncommercial-No Derivative Works 4.0
Projects:
Project IDFunderFunder ID
K23HL135438National Institutes of Healthhttp://dx.doi.org/10.13039/100000002
R21AG063143National Heart, Lung, and Blood Institutehttp://dx.doi.org/10.13039/100000050
K08 HL130945National Heart, Lung, and Blood Institutehttp://dx.doi.org/10.13039/100000050
K01 HL138172National Heart, Lung, and Blood Institutehttp://dx.doi.org/10.13039/100000050
R01 HL146158National Heart, Lung, and Blood Institutehttp://dx.doi.org/10.13039/100000050
AG065141National Heart, Lung, and Blood Institutehttp://dx.doi.org/10.13039/100000050
R01 HL152162National Heart, Lung, and Blood Institutehttp://dx.doi.org/10.13039/100000050
R21 HL152264National Heart, Lung, and Blood Institutehttp://dx.doi.org/10.13039/100000050
R01 HL132448National Heart, Lung, and Blood Institutehttp://dx.doi.org/10.13039/100000050
UM1 HL087366National Heart, Lung, and Blood Institutehttp://dx.doi.org/10.13039/100000050
UM1 HL087318National Heart, Lung, and Blood Institutehttp://dx.doi.org/10.13039/100000050
UL1 TR001427National Center for Advancing Translational Scienceshttp://dx.doi.org/10.13039/100006108
W81XWH-17-2-0030U.S. Department of Defensehttp://dx.doi.org/10.13039/100000005
RE/18/6134217British Heart Foundationhttp://dx.doi.org/10.13039/501100000274
EP/R511705/1Engineering and Physical Sciences Research Councilhttp://dx.doi.org/10.13039/501100000266
EP/S030875/1Engineering and Physical Sciences Research Councilhttp://dx.doi.org/10.13039/501100000266
754946-2European UnionUNSPECIFIED
MR/S018905/1Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
MC/PC/20014UK Research and Innovationhttp://dx.doi.org/10.13039/100014013
URI: https://openaccess.sgul.ac.uk/id/eprint/114710
Publisher's version: https://doi.org/10.1016/j.jacc.2022.08.814

Actions (login required)

Edit Item Edit Item